Navigation Links
Lonza and BioWa Sign License Agreements with FivePrime Therapeutics for Use of Their POTELLIGENT® CHOK1SV Cell Line for Therapeutic Antibody Development
Date:6/12/2012

PRINCETON, N.J., BASEL, Switzerland and SOUTH SAN FRANCISCO, Calif., June 13, 2012 /PRNewswire/ -- Five Prime Therapeutics, Inc. ("FivePrime") has entered into research and commercial agreements with BioWa, Inc. and Lonza to use their POTELLIGENT® CHOK1SV Cell Line for the research, development and production of multiple proprietary antibodies in FivePrime's oncology pipeline. 

POTELLIGENT® CHOK1SV is a host cell line for manufacturing recombinant antibodies that combines the power of BioWa's engineered glycosylation POTELLIGENT® Technology with the advantages of Lonza's proprietary GS Gene Expression System™, which includes the industry-leading CHOK1SV cell line.

"We are pleased to offer the POTELLIGENT® CHOK1SV Cell Line as a key component to therapeutic antibody development," said Janet White, Head of Lonza Development Services. "We look forward to supporting FivePrime's R&D and clinical programs with this new strategic collaboration."

"We are pleased that the value of our POTELLIGENT® Technology continues to be recognized by innovative companies such as FivePrime for their biotherapeutic programs in oncology," said Yasunori Yamaguchi, PhD, President and CEO of BioWa.

"The combination of the clinical validation seen with other POTELLIGENT® antibodies and the track record of the GS cell line were key to our decision to select this system to enhance the potential for therapeutic efficacy of our emerging pipeline of antibodies in oncology," said Michael Kavanaugh, MD, Senior Vice President, Research and Development of FivePrime.

The POTELLIGENT® CHOK1SV Cell Line retains the desirable features of a high-producing cell line (robust, high-yielding, scalable), with the advantage of a proven bioprocess platform for the CHOK1SV cell line.  Antibodies produced by this cell line exhibit enhanced antibody dependent cellular cytotoxicity (ADCC) and can exert potent cytotoxic e
'/>"/>

SOURCE BioWa, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Biodel Obtains Exclusive License to Aegis Therapeutics Technologies for Development and Commercialization of Glucagon Pharmaceutical Formulations
2. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
3. NTT DATA Licenses DATATRAK ONE™ for China
4. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
5. CASiGEN Pharma Receives A World-wide Exclusive License From GIBH To Bring New Potential Diabetes Treatments To The Global Market
6. Islet Sciences Announces Exclusive License Agreement with Yale University to Commercialize an Early Beta Cell Destruction and Diabetes Diagnostic
7. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
8. MetaStat, Inc. Executes Two New Licenses
9. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
10. Novelos Therapeutics Prices $5.4 Million Public Offering
11. Sorrento Therapeutics Awarded Third Phase I STTR Grant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... PHOENIX , Sept. 22, 2014  For ... wrists, surgery often means facing the prospect of ... can be imagined, regular activities are also impacted, ... on the severity of the problem, some patients ... braces, which can even lead to permanent damage ...
(Date:9/22/2014)... Sept. 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... initiated a phase I clinical trial in patients ... safety, tolerability, and immunogenicity of INO-3106. This immunotherapy ... most aerodigestive cancers. Aerodigestive cancers affect ... and parts of the esophagus and windpipe. The ...
(Date:9/22/2014)... , Sept. 22, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... pleased to announce that TUV-SUD and The Medicinal ... (MEB) has granted its request for a ... Neutrolin was initially approved in July 2013 for ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4Neutrolin Label Expansion Approved for the European Union 2Neutrolin Label Expansion Approved for the European Union 3
(Date:9/22/2014)... UK (PRWEB) September 22, 2014 The ... in the recent years. The statistically important data received ... safety of cancer vaccines. The primary challenge to the ... information about the exact mechanism of how a human’s ... to various results in different individuals owing to known ...
(Date:9/22/2014)... New York, New York (PRWEB) September 22, 2014 ... risks associated with the use of power morcellators ... Liebhard LLP notes a new report detailing the ... despite warnings from federal regulators that specifically discouraged ... these physicians believe that the potential cancer risks ...
(Date:9/22/2014)... 2014 (HealthDay News) -- Two new prescription devices approved ... provide some relief for people with migraine headaches who ... study. One device -- the Cefaly -- is ... the Cerena -- is meant to be used when ... "Patients have been looking for alternative migraine treatments. ...
(Date:9/22/2014)... CareFlight Air & Mobile Services ... a new AS365 N3+ Dauphin, the latest version of ... which is based at Miami Valley Hospital ... air medical transport helicopters. , “We have a lot ... Health Vice President, Emergency, Trauma, and CareFlight. “We’ve been ...
(Date:9/22/2014)... In a continued effort to support the ... launching an awareness campaign inspired by the ice bucket ... to raise awareness and funds for the cause. , ... the air and trying to catch it while blindfolded. ... nominee does not complete the challenge within 24 hours ...
Breaking Medicine News(10 mins):Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 2Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 3Health News:World Cancer Vaccines Market Landscape Examined by Kuick Research in New Study Published at MarketPublishers.com 4Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 2Health News:Miami Valley Hospital CareFlight begins Service with AS365 N3+ 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2
... SETO Holdings, Inc. (Pink Sheets: SETO) announced that it signed ... (1) to issue shares of its Common Stock to acquire ... ("AHC"), a Maryland corporation which provides hearing services and retails ... Virginia, and (2) to sell all of SETO,s current businesses, ...
... how that happens may lead to ways around it, ... Temozolomide, a standard treatment for brain cancer, may boost ... more likely, a new study suggests. , The research ... City, have identified cells in brain tumors called gliomas ...
... Company Records 172% Year over Year Revenue Growth and ... Insulet,s International ExpansionBrian Roberts Appointed CFOBEDFORD, Mass., March 5 ... leader in tubing-free insulin pump technology with its OmniPod(R) ... fourth quarter and full year ended December 31, 2008. ...
... SEATTLE, March 5 Trubion Pharmaceuticals Inc. (Nasdaq: ... issue earnings results for the fourth quarter and year ... on March 12, 2009. The company,s earnings conference call ... Pacific Time, 5 p.m. Eastern Time. Both live events ...
... editors of the Harvard Health Letter , in consultation with the ... health care spending, saving society--and perhaps yourself--some money , ... Boston, MA ... will falter unless health care spending is brought under control. Moreover, even ...
... OpportunitiesHARRISBURG, Pa., March 5 Insurance Commissioner ... off from a job that offered health insurance to ... them with relief on premiums and that now is ... want to let Pennsylvanians know that additional help in ...
Cached Medicine News:Health News:SETO Holdings, Inc. Signs Letter of Intent to Dispose of all its Existing Businesses and Acquire Advanced Hearing Centers, Inc.; New Management to be Installed. 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 2Health News:Brain Tumor Drug May Help Spur Cancer's Return 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 2Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 3Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 4Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 5Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 6Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 7Health News:Insulet Reports Fourth Quarter and Year End 2008 Results 8Health News:Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 2Health News:Runaway Health Care Costs: 12 Ways You Can Rein Them in, from the Harvard Health Letter 3Health News:Pennsylvanians Encouraged to Take Another Look at COBRA Options 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: